Cargando…

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions

SIMPLE SUMMARY: Oncology is a rapidly advancing field in small-animal medicine, underscoring the importance of innovative therapeutic approaches. Tyrosine kinase inhibitors (TKIs) are drugs that block various important cellular functions and play an important role in treating cancer in people and do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Žagar, Žiga, Schmidt, Jarno M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572079/ https://www.ncbi.nlm.nih.gov/pubmed/37835664 http://dx.doi.org/10.3390/ani13193059

Ejemplares similares

A scoping review of risk-stratified bowel screening: current evidence, future directions
por: Cairns, J. M., et al.
Publicado: (2022)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
por: Juric, Viktorija, et al.
Publicado: (2020)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
por: Qiu, Le, et al.
Publicado: (2014)

The current situation and future directions for the study on time-to-pregnancy: a scoping review
por: Hong, Xiang, et al.
Publicado: (2022)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
por: Havelange, Violaine, et al.
Publicado: (2013)

Bioinformatics Education in Pathology Training: Current Scope and Future Direction
por: Clay, Michael R, et al.
Publicado: (2017)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
por: San Román Gil, María, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
por: Sammarco, Enrico, et al.
Publicado: (2023)

Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
por: Sadeghi, Sara, et al.
Publicado: (2022)

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
por: Arena, Claudia, et al.
Publicado: (2018)

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
por: Yang, Yang, et al.
Publicado: (2022)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
por: Pitsiou, Georgia, et al.
Publicado: (2014)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

Disparities in Glaucoma Surgery: A Review of Current Evidence and Future Directions for Improvement
por: Tseng, Victoria L., et al.
Publicado: (2023)

The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
por: Lan, Nick S.R., et al.
Publicado: (2019)

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms
por: Kutsch, Nadine, et al.
Publicado: (2015)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
por: Kreidieh, Malek, et al.
Publicado: (2020)

Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
por: Tschöpe, Carsten, et al.
Publicado: (2020)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kekbpcqifkif1qv40bkv04tdq0